Notes
Medicare (2010−2015; IMS PharMetrics (2011−2015); Truven MarketScan (2011−2015)
Reference
Pawar A, et al. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Annals of the Rheumatic Diseases : 24 Jan 2019. Available from: URL: http://doi.org/10.1136/annrheumdis-2018-214367
Rights and permissions
About this article
Cite this article
Serious infections with tocilizumab in rheumatoid arthritis. Reactions Weekly 1739, 13 (2019). https://doi.org/10.1007/s40278-019-57653-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-57653-8